Hormone replacement therapy in Leber's hereditary optic neuropathy: Accelerated visual recovery in vivo
Hormone replacement therapy in Leber's hereditary optic neuropathy: Accelerated visual recovery in vivo
复制标题
DOI：
10.1016/j.joco.2018.10.003
复制
发表时间：
2019-03-01
影响因子：
1.5
通讯作者：
Sadun, Alfredo
中科院分区：
文献类型：
--
作者：
Fantini, Michele;Asanad, Samuel;Sadun, Alfredo
目的：报告一例莱伯遗传性视神经病变 (LHON) 病例在使用艾地苯醌和激素替代疗法 (HRT) 治疗后视力恢复的加速过程。我们在此证明了雌激素在体内 LHON 中的保护作用的临床效用。方法：我们介绍了一名携带 10197 线粒体 DNA (mtDNA) 突变的绝经期妇女的 LHON 病例，该妇女在停止雌激素替代疗法后不久就出现了视力丧失。报告了艾地苯醌和 HRT 治疗后的功能性视觉结果。结果：患者表现出视力恢复的加速过程，早在 1 个月内就出现视力改善，并在治疗后 8 个月完全逆转视力丧失。结论：艾地苯醌治疗联合 HRT 可能在增强细胞生物能方面具有协同作用，并可能解释患者视力加速改善的原因。版权所有 (C) 2018，伊朗眼科学会。由 Elsevier B.V. 制作和主持
Purpose: To report an accelerated course of visual recovery in a case of Leber's hereditary optic neuropathy (LHON) following treatment with idebenone and hormone replacement therapy (HRT). We hereby demonstrate the clinical utility of estrogen's protective role in LHON in vivo.Methods: We present a case of LHON in a menopausal woman carrying the 10197 mitochondrial DNA (mtDNA) mutation, who experienced loss of vision shortly after discontinuing her estrogen replacement regimen. Functional visual outcomes are reported following treatment with idebenone and HRT.Results: The patient exhibited an accelerated course of visual recovery, experiencing improvement in vision as early as one month and complete reversal of vision loss by eight months post-therapy.Conclusion: Idebenone treatment combined with HRT may have a synergistic effect in enhancing cellular bioenergetics and may explain the patient's accelerated visual improvement. Copyright (C) 2018, Iranian Society of Ophthalmology. Production and hosting by Elsevier B.V.